Understand the regulatory and policy considerations for running clinical trial recruitment campaigns on nontraditional or ...

Epkinly plus rituximab and lenalidomide is the first bispecific antibody combination FDA-approved for relapsed or refractory follicular lymphoma, backed by Phase III data showing substantially ...

Emerging applications of AI/ML, automation, and digitization are helping sponsors cut clinical trial start-up times to as little as four weeks, reduce data errors, and enhance patient ...

As clinical research evolves, integrated technologies are reshaping patient and site experiences through AI, remote monitoring, and next-generation telehealth. Join IQVIA experts Chris Driver and Dan ...

In today’s ACT Brief, we look at how Trialbee evaluates nontraditional digital platforms for patient recruitment, review new ...

Learn how demographic and behavioral insights inform platform-specific messaging, creative formats, and call-to-action ...

Explore which factors—audience relevance, content fit, and engagement quality—determine the best use of platforms like TikTok ...

In today’s ACT Brief, we look at how real-world data and AI are helping prevent costly study rescue, review the FDA’s ...

ACT: At this year’s SCRS Summit, several site representatives raised concerns about overly complex protocols and patient ...

How sponsors can leverage technology to enhance, not hinder, site efficiency and usability Strategies to incorporate site ...

Tremfya demonstrated sustained reduction in PsA symptoms and inhibited structural damage progression at 48 weeks in the APEX trial. Patients switching from placebo to Tremfya experienced a 57% ...

In today’s ACT Brief, we examine declining site satisfaction and strategies to improve sponsor-site collaboration, review a ...